OR WAIT null SECS
January 08, 2025
Article
The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.
CT-P42 may help improve access to aflibercept in lower-income countries.
December 26, 2024
December 18, 2024
Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.
December 06, 2024
The biosimilars month in review highlights new equivalency data for denosumab and tocilizumab biosimilars.
Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.
December 03, 2024
CT-P41 had similar rates of bone mineral density increases and adverse events in data presented at the ACR 2024 Convergence.
November 06, 2024
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.
November 02, 2024
The biosimilars month in review highlights new approvals, new safety findings, and new cost savings with biosimilars.
October 22, 2024
Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.
